

A randomised, double-blind, crossover comparison of the efficacy and safety of study drug 017 and placebo in patients with neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN)

Submission date 25/03/2008	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 04/07/2008	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 04/07/2008	Condition category Nervous System Diseases	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr John Eisenhoffer

Contact details
Purdue Pharma
575 Granite Court
Pickering, Ontario
Canada
L1W 3W8
+1 905 420 6400
medinfo@purdue.ca

Additional identifiers

Protocol serial number
017-010

Study information

Scientific Title

Study objectives

Study drug 017 will be superior to placebo in the treatment of chronic neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval for the lead centre was received from Institutional Review Board (IRB) Services, Aurora, ON (Canada) on 11 January 2008. All other participating centres obtained ethics approval before recruiting study participants.

Primary study design

Interventional

Study design

Multi-centred, randomised, double-blind, placebo-controlled crossover trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Neuropathic pain

Interventions

Centrally-acting oral opioid analgesic (017) titrated to effect over a 4-week phase with matched placebo arm.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Study drug 017 (a centrally acting opioid analgesic)

Primary outcome(s)

Pain intensity measured during the last week of treatment in each phase.

Key secondary outcome(s)

All assessments measured during the last week of treatment in each phase:

1. Neuropathic Pain Scale
2. Pain and sleep
3. Pain and disability

- 4. Quality of life
- 5. Depression inventory

Completion date

31/12/2009

Eligibility

Key inclusion criteria

For diabetic neuropathy patients:

1. Stable glycaemic control
2. Patients with pain in the lower extremities on a daily basis and one or more signs or symptoms of peripheral neuropathy not attributable to any other cause
3. Patients with absent or decreased ankle reflexes and loss of perception of 128 Hz vibration of the great toe

For post-herpetic neuralgia patients:

1. Primary diagnosis of PHN defined by pain for at least three months after healing of a herpes zoster skin rash

For all patients:

1. Male or non-pregnant females at least 18 years of age
2. Patients who answer yes to at least four items on the the neuropathic pain diagnostic questionnaire (DN4)
3. Patients whose pain has been of moderate intensity on most days for at least three months
4. Patients who have required the use of analgesic medication for at least three months

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Patients who do not have stable glycaemic control (HbA1c greater than 2 x normal) or whose anti-diabetic therapy is likely to require adjustment during the study
2. Patients with peripheral neuropathy attributable to other causes
3. Significant pain of other origin that may obscure the assessment of efficacy
4. Patients whose opioid requirement may exceed eight tablets of acetaminophen plus codeine (300/30 mg) or analgesic equivalent per day
5. Patients with true allergy to acetaminophen or any opioid, sufficient that therapy is

contraindicated

6. Patients with any of the following medical conditions:

6.1. Active, severe psychiatric disorder, including severe depression

6.2. Postural hypotension

6.3. Clinically significant hepatic dysfunction (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [Alk Phos] greater than 2 x normal)

6.4. Symptomatic coronary artery peripheral vascular disease

6.5. Intermittent claudication

6.6. Brittle diabetes

6.7. Low serum cobalamin (vitamin B12)

6.8. Abnormal serum folic acid levels

6.9. Colostomy, ileostomy or shortened gastrointestinal (GI) transit time

6.10. Active or recent peptic ulcer or gastrointestinal (GI) inflammatory disease

6.11. Epilepsy, history of seizures or recognised risk for seizure

6.12. Any condition that may adversely affect patient safety or obscure assessment of efficacy

7. Patients receiving any of the following medications:

7.1. Monoamine oxidase inhibitors

7.2. Carbamazepine

7.3. Quinidine

7.4. Selective serotonin reuptake inhibitors

7.5. Serotonin norepinephrine reuptake inhibitors

7.6. Neuroleptics

7.7. Warfarin

7.8. Digoxin

8. Patients who have received an investigational drug within the previous month

9. Patients with a known or suspected history of drug or alcohol abuse

Date of first enrolment

21/01/2008

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

Canada

Study participating centre

Purdue Pharma

Pickering, Ontario

Canada

L1W 3W8

Sponsor information

Organisation

Purdue Pharma Canada

ROR

<https://ror.org/023sxys58>

Funder(s)**Funder type**

Industry

Funder Name

Purdue Pharma Canada

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration